UCB Pharma has launched Vimpat (lacosamide) for adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients aged 16 years and over with epilepsy.

Lacosamide has an innovative mode of action and a unique binding site. It is thought to exert its anti-epileptic effect by selectively enhancing slow inactivation of sodium channels and binding to collapsin response mediator protein-2 (CRMP-2).1,2 The precise mechanism of action remains to be fully elucidated.

Pooled trial data show that lacosamide improved seizure control compared to, and regardless of, current or prior anti-epileptic therapy.3

These trials, involving 1308 patients, were designed to evaluate the efficacy and safety of lacosamide when administered concomitantly with one to three anti-epileptic drugs in patients with uncontrolled partial-onset seizures, with or without secondary generalisation.

Overall, the proportion of subjects with a 50% reduction in seizure frequency was 23%, 34%, and 40% for placebo, lacosamide 200mg daily and lacosamide 400mg daily, respectively.1,3

Data from an ongoing study suggest that long-term treatment with lacosamide (currently up to 5.5 years) has high long-term retention rates (77% after one year),4 and is generally well tolerated.1,3

View Vimpat drug record

1. Vimpat Summary of Product Characteristics.
2. Beyreuther BK, Freitag J, Heers C et al. Lacosamide: a review of preclinical properties. CNS Drug Reviews 2007; 13:21-42.
3. UCB Pharma Ltd. Data on file.
4. Rosenfeld W, Fountain NB, Kaubrys G et al. Lacosamide: an interim evaluation of long-term safety and efficacy as oral adjunctive therapy in subjects with partial-onset seizures. Presented at the 61st Annual American Epilepsy Society Meeting, 2007, Philadelphia.

Further information: UCB Pharma

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases